Cargando…

Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity

OBJECTIVE: The aim of the present study was to formulate the anticancer drug; docetaxel (DOX) as nanoparticles to enhance its biological activity. METHODOLOGY: Solvent precipitation method was used to prepare DOX-loaded nanoparticles and was stabilized by different concentrations of hydroxypropyl me...

Descripción completa

Detalles Bibliográficos
Autores principales: Ibrahim, Mohamed A., Shazly, Gamal A., Aleanizy, Fadilah S., Alqahtani, Fulwah Y., Elosaily, Gehan M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323146/
https://www.ncbi.nlm.nih.gov/pubmed/30662306
http://dx.doi.org/10.1016/j.jsps.2018.07.018
_version_ 1783385701853691904
author Ibrahim, Mohamed A.
Shazly, Gamal A.
Aleanizy, Fadilah S.
Alqahtani, Fulwah Y.
Elosaily, Gehan M.
author_facet Ibrahim, Mohamed A.
Shazly, Gamal A.
Aleanizy, Fadilah S.
Alqahtani, Fulwah Y.
Elosaily, Gehan M.
author_sort Ibrahim, Mohamed A.
collection PubMed
description OBJECTIVE: The aim of the present study was to formulate the anticancer drug; docetaxel (DOX) as nanoparticles to enhance its biological activity. METHODOLOGY: Solvent precipitation method was used to prepare DOX-loaded nanoparticles and was stabilized by different concentrations of hydroxypropyl methylcellulose (HPMC, E5) and sodium deoxycholate (SDC). RESULTS: The results showed that the particle size of the prepared DOX nanoparticles stabilized by SDC was small in comparison to those stabilized by the corresponding HPMC concentrations. The smallest particle size (83.97 nm) was obtained by using SDC as stabilizer at 5% level with zeta potential of −13.6 mV. It was concluded that increasing the stabilizer concentration resulted in increase in both initial and overall cumulative drug release. The release rate in case of nanoparticles stabilized by 5% SDC was 33% and 87% after 1 and 24 h respectively. The results showed that a significant reduction in the viability of FRO cells was observed at all tested time intervals in case of nanoparticles stabilized by 5% SDC at concentrations of 100 and 1000 μM/ml. In contrast, no signs of cytotoxicity was observed for nanoparticles stabilized by 5% HPMC at 10 and 100 μM/ml concentrations.
format Online
Article
Text
id pubmed-6323146
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63231462019-01-18 Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity Ibrahim, Mohamed A. Shazly, Gamal A. Aleanizy, Fadilah S. Alqahtani, Fulwah Y. Elosaily, Gehan M. Saudi Pharm J Article OBJECTIVE: The aim of the present study was to formulate the anticancer drug; docetaxel (DOX) as nanoparticles to enhance its biological activity. METHODOLOGY: Solvent precipitation method was used to prepare DOX-loaded nanoparticles and was stabilized by different concentrations of hydroxypropyl methylcellulose (HPMC, E5) and sodium deoxycholate (SDC). RESULTS: The results showed that the particle size of the prepared DOX nanoparticles stabilized by SDC was small in comparison to those stabilized by the corresponding HPMC concentrations. The smallest particle size (83.97 nm) was obtained by using SDC as stabilizer at 5% level with zeta potential of −13.6 mV. It was concluded that increasing the stabilizer concentration resulted in increase in both initial and overall cumulative drug release. The release rate in case of nanoparticles stabilized by 5% SDC was 33% and 87% after 1 and 24 h respectively. The results showed that a significant reduction in the viability of FRO cells was observed at all tested time intervals in case of nanoparticles stabilized by 5% SDC at concentrations of 100 and 1000 μM/ml. In contrast, no signs of cytotoxicity was observed for nanoparticles stabilized by 5% HPMC at 10 and 100 μM/ml concentrations. Elsevier 2019-01 2018-07-20 /pmc/articles/PMC6323146/ /pubmed/30662306 http://dx.doi.org/10.1016/j.jsps.2018.07.018 Text en © 2018 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Ibrahim, Mohamed A.
Shazly, Gamal A.
Aleanizy, Fadilah S.
Alqahtani, Fulwah Y.
Elosaily, Gehan M.
Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
title Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
title_full Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
title_fullStr Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
title_full_unstemmed Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
title_short Formulation and evaluation of docetaxel nanosuspensions: In-vitro evaluation and cytotoxicity
title_sort formulation and evaluation of docetaxel nanosuspensions: in-vitro evaluation and cytotoxicity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323146/
https://www.ncbi.nlm.nih.gov/pubmed/30662306
http://dx.doi.org/10.1016/j.jsps.2018.07.018
work_keys_str_mv AT ibrahimmohameda formulationandevaluationofdocetaxelnanosuspensionsinvitroevaluationandcytotoxicity
AT shazlygamala formulationandevaluationofdocetaxelnanosuspensionsinvitroevaluationandcytotoxicity
AT aleanizyfadilahs formulationandevaluationofdocetaxelnanosuspensionsinvitroevaluationandcytotoxicity
AT alqahtanifulwahy formulationandevaluationofdocetaxelnanosuspensionsinvitroevaluationandcytotoxicity
AT elosailygehanm formulationandevaluationofdocetaxelnanosuspensionsinvitroevaluationandcytotoxicity